Terms: = Breast cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4
466 results:
1. Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive breast cancer Cell Lines.
Sanz-Álvarez M; Luque M; Morales-Gallego M; Cristóbal I; Ramírez-Merino N; Rangel Y; Izarzugaza Y; Eroles P; Albanell J; Madoz-Gúrpide J; Rojo F
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203378
[TBL] [Abstract] [Full Text] [Related]
2. Metastatic Lymph Node 64 (MLN64) Expression in Gastric cancer: The Clinical and Molecular Implications in Drug Resistance.
Li AX; Zeng JJ; Khan E; Dou QP; Zhuang X; Ji EK; Ruge F; Martin TA; Jia S; Jiang WG
Cancer Genomics Proteomics; 2024; 21(1):30-40. PubMed ID: 38151289
[TBL] [Abstract] [Full Text] [Related]
3. Novel Pathways between Invasiveness Modulators in breast cancer Single Cells.
Eliceiri GL
Crit Rev Eukaryot Gene Expr; 2024; 34(2):73-75. PubMed ID: 38073443
[TBL] [Abstract] [Full Text] [Related]
4. Neratinib for HER2-positive breast cancer with an overlooked option.
Guo L; Shao W; Zhou C; Yang H; Yang L; Cai Q; Wang J; Shi Y; Huang L; Zhang J
Mol Med; 2023 Oct; 29(1):134. PubMed ID: 37803271
[TBL] [Abstract] [Full Text] [Related]
5. Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer.
Dai LJ; Ma D; Xu YZ; Li M; Li YW; Xiao Y; Jin X; Wu SY; Zhao YX; Wang H; Yang WT; Jiang YZ; Shao ZM
Nat Commun; 2023 Aug; 14(1):5112. PubMed ID: 37607916
[TBL] [Abstract] [Full Text] [Related]
6. Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy.
Chaudhary LN; Jorns JM; Sun Y; Cheng YC; Kamaraju S; Burfeind J; Gonyo MB; Kong AL; Patten C; Yen T; Cortina CS; Carson E; Johnson N; Bergom C; Tsaih SW; Banerjee A; Wang Y; Chervoneva I; Weil E; Chitambar CR; Rui H
Breast Cancer Res Treat; 2023 Oct; 201(3):387-396. PubMed ID: 37460683
[TBL] [Abstract] [Full Text] [Related]
7. Giant juvenile fibroadenomas with and without prominent pseudoangiomatous stromal hyperplasia (PASH)-like change: clinicopathological and molecular characteristics.
Jorns JM; Farooq A; Puzyrenko A; Jarzembowski J; Thike AA; Nasir NDM; Ng CCY; Liu W; Lee JY; Lim AH; Guan P; Teh BT; Tan PH
Histopathology; 2023 Sep; 83(3):357-365. PubMed ID: 37140543
[TBL] [Abstract] [Full Text] [Related]
8. Vitamin D analog calcitriol for breast cancer therapy; an integrated drug discovery approach.
B S N; P K KN; Akey KS; Sankaran S; Raman RK; Natarajan J; Selvaraj J
J Biomol Struct Dyn; 2023 Dec; 41(20):11017-11043. PubMed ID: 37054526
[TBL] [Abstract] [Full Text] [Related]
9. Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.
Tawfeeq N; Lazarte JMS; Jin Y; Gregory MD; Lamango NS
Oncotarget; 2023 Mar; 14():243-257. PubMed ID: 36961909
[TBL] [Abstract] [Full Text] [Related]
10. erbb4-encoded novel miRNAs act as tumor suppressors by regulating ErbB/PI3K signaling.
Ghaemi Z; Soltani BM; Mowla SJ
Tumour Biol; 2022; 44(1):215-230. PubMed ID: 36442170
[TBL] [Abstract] [Full Text] [Related]
11. Deciphering the Role and Signaling Pathways of PKCα in Luminal A breast cancer Cells.
Serrano-López EM; Coronado-Parra T; Marín-Vicente C; Szallasi Z; Gómez-Abellán V; López-Andreo MJ; Gragera M; Gómez-Fernández JC; López-Nicolás R; Corbalán-García S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430510
[TBL] [Abstract] [Full Text] [Related]
12. Life after Cleavage: The Story of a β-Retroviral (MMTV) Signal Peptide-From Murine Lymphoma to Human breast cancer.
Hochman J; Braitbard O
Viruses; 2022 Nov; 14(11):. PubMed ID: 36366533
[TBL] [Abstract] [Full Text] [Related]
13. Etoposide-induced MicroRNA-205-5p Suppresses Proliferation and Migration by Targeting erbb4 in MCF-7 Cells.
Son SW; Heo SH; Oh SS; Lee CH; Park JK
Anticancer Res; 2022 Sep; 42(9):4265-4272. PubMed ID: 36039421
[TBL] [Abstract] [Full Text] [Related]
14. Beyond HER2: Targeting the ErbB receptor family in breast cancer.
Drago JZ; Ferraro E; Abuhadra N; Modi S
Cancer Treat Rev; 2022 Sep; 109():102436. PubMed ID: 35870237
[TBL] [Abstract] [Full Text] [Related]
15. Expression of ERBB gene family in females with breast cancer and its correlation with clinicopathological characteristics of the disease.
Soosanabadi M; Ghahfarokhi AM; Pourghazi F; Ehtesham N; Mirfakhraie R; Atanesyan L; Keyhani E; Behjati F
Mol Biol Rep; 2022 Sep; 49(9):8547-8553. PubMed ID: 35763181
[TBL] [Abstract] [Full Text] [Related]
16. A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.
Salawu A; Hansen AR; Spreafico A; Al-Ezzi E; Webster S; Bedard PL; Doi J; Wang L; Siu LL; Abdul Razak AR
Target Oncol; 2022 May; 17(3):271-281. PubMed ID: 35635640
[TBL] [Abstract] [Full Text] [Related]
17. Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients.
Ramić S; Paić F; Smajlbegović V; Perić Balja M; Hiršl L; Marton I; Knežević F
Croat Med J; 2022 Apr; 63(2):126-140. PubMed ID: 35505646
[TBL] [Abstract] [Full Text] [Related]
18. The HER family as therapeutic targets in colorectal cancer.
Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
[TBL] [Abstract] [Full Text] [Related]
19. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
20. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal cancer: A Review.
Strickler JH; Yoshino T; Graham RP; Siena S; Bekaii-Saab T
JAMA Oncol; 2022 May; 8(5):760-769. PubMed ID: 35238866
[TBL] [Abstract] [Full Text] [Related]
[Next]
